Posted by Michael Wonder on 01 Apr 2025
European Commission approves Pfizer’s RSV vaccine Abrysvo to help protect adults aged 18-59 against RSV lower respiratory tract disease
1 April 2025 - Abrysvo is the first and only RSV vaccine approved in the European Union for non-pregnant adults aged 18-49.
Pfizer announced today that the European Commission has issued a decision amending the marketing authorisation for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) pre-fusion F vaccine, to extend the indication to include prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age.
